BRIEF — Amryt in further distribution deal for Lojuxta

UK biopharma Amryt Pharma has announced another distribution deal for Lojuxta (lomitapide) – this time covering Lebanon, Jordan and Syria.

Lojuxta is a therapy used to treat adult patients with homozygous familial hypercholesterolaemia (HoFH), a rare, life-threatening, genetic cholesterol disorder.

The agreement is with Pharaon Healthcare-Droguerie Mercury, one of the leading full-service distributors in the region.

Joe Wiley, chief executive of Amryt Pharma, said: “This is Amryt’s fifth new distribution agreement for Lojuxta in approximately three months, and we are delighted to be partnering with Pharaon Healthcare in Lebanon, Jordan and Syria.

“Pharaon Healthcare has an excellent footprint and many decades of experience in these markets, and this new agreement should help to ensure we can respond effectively to physicians’ requests regarding their patients suffering with HoFH.”